ImmuCell Q1 2026 net income $1.9M, product sales up 28.4% to $10.4M

IMMUCELL CORP /DE/

2026-Q1 EPS reported $0.21 revenue$10,357,295

Net income $1.9M ($0.21/share) vs $1.4M ($0.16/share) in Q1 2025.
Product sales $10.4M, up 28.4% YoY; gross margin 45.0% vs 41.6%.
Cash position $6.8M at Mar 31, 2026, up from $3.8M; generated $3.4M free cash flow in Q1.
Settled all disputes with former contract manufacturer for net $2M payment to ImmuCell, to fund capacity expansion.
Manufacturing output increased to >450K units/month from ~380K in 2025.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.